Atherosclerosis Or Coronary Artery Disease (CAD) - Drug Pipeline Analysis and Market Forecasts to 2016

Atherosclerosis Or Coronary Artery Disease (CAD) - Drug Pipeline Analysis and Market Forecasts to 2016

Summary

GlobalData, the industry analysis specialist’s new report, “Atherosclerosis Or Coronary Artery Disease (CAD) – Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global atherosclerosis market. The report identifies the key trends shaping and driving the global atherosclerosis market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global atherosclerosis sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Scope

The scope of the report includes:

• Annualized global atherosclerosis revenues data from 2001 to 2009, forecast forward for 7 years to 2016.
• Geographic markets covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France, and Japan.
• Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends.
• Analysis of the current and future market competition in the global atherosclerosis market.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the future market associated with atherosclerosis.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

• Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global atherosclerosis market.
• Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global atherosclerosis market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global atherosclerosis market landscape? – Identify, understand and capitalize.

1 Table of contents

1.1 List of Tables

1.2 List of Figures

2 Coronary Artery Disease: Market Characterization

2.1 Overview

2.2 Coronary Artery Disease Market Size

2.3 Coronary Artery Disease Market Forecast and CAGR

2.4 Drivers and Barriers for the Coronary Artery Disease Market

2.4.1 Drivers of the Coronary Artery Disease Market

2.4.2 Barriers for the Coronary Artery Disease Market

2.5 Opportunity and Unmet Need

2.6 Key Takeaway

3 Coronary Aartery Disease: Competitive Assessment

3.1 Overview

3.2 Strategic Competitor Assessment

3.3 Product Profile for the Major Marketed Products in the Coronary Artery Disease Market

3.3.1 Lipitor

3.3.2 Crestor

3.3.3 Plavix

3.3.4 Pravachol (pravastatin sodium)

3.3.5 Niaspan (Niacin)

3.4 Key Takeaway

4 Coronary Artery Disease: Pipeline Assessment

4.1 Overview

4.2 Strategic Pipeline Assessment

4.2.1 Technology Trends Analytic Framework

4.3 Coronary Artery Disease Therapeutics - Promising Drugs under Clinical Development

4.4 Drugs under Clinical Development

4.4.1 Darapladib

4.4.2 Anacetrapib

4.4.3 Aliskiren

4.4.4 SCH 530348

4.5 Coronary Artery Disease Therapeutics Market - Clinical Pipeline by Mechanism of Action

4.6 Coronary Artery Disease Pipeline - Pipeline by Clinical Phases of Development

4.6.1 Coronary Artery Disease Therapeutics - Phase III Clinical Pipeline

4.6.2 Coronary Artery Disease Therapeutics - Phase II Clinical Pipeline

4.6.3 Coronary Artery Disease Therapeutics - Phase I Clinical Pipeline

4.6.4 Coronary Artery Disease Therapeutics - Preclinical Pipeline

4.7 Discontinued / Suspended Drugs for Coronary Artery Disease

4.8 Key Takeaway

5 Coronary Artery Disease Market: Implications for Future Market Competition

6 Coronary Artery Disease Market: Future Players in the Cornary Artery Disease Market

6.1 Introduction

6.2 GlaxoSmithKline plc

6.2.1 Overview

6.2.2 Business Description

6.2.3 Cardiovascular Portfolio

6.2.4 Coronary Artery Disease Product Portfolio

6.3 Novartis AG

6.3.1 Overview

6.3.2 Business Description

6.3.3 Cardiovascular Portfolio

6.3.4 Coronary Artery Disease Product Portfolio

6.4 Merck & Co., Inc.

6.4.1 Overview

6.4.2 Business Description

6.4.3 Cardiovascular Portfolio

6.4.4 Coronary Artery Disease product portfolio

7 Coronary Artery Disease: Appendix

7.1 Definitions

7.2 Acronyms

7.3 Research Methodology

7.3.1 Coverage

7.3.2 Secondary Research

7.3.3 Forecasting

7.3.4 Primary Research

7.3.5 Expert Panels

7.4 Contact Us

7.5 Disclaimer

7.6 Sources